Key Takeaways
- Strong quarter, supply chains still tight: Revenue grew 29.5% YoY and EBITDA margins expanded 170 bps, even as geopolitical disruptions kept freight costs at 2x to 3x normal levels.
- The HAL JV is on the cusp of production: The plant is broadly ready, exhibit batches start in December, and a full revenue quarter is on track for Q1 CY25, with project costs coming in under estimate.
- Product portfolio is the long-term engine: Management targets 15-20 launches per year and an eventual export portfolio of 280 to 300 products, up from 145-150 today, with margins improving as products mature across multiple buyers.
- New ventures are early but promising: The Prague nutraceutical JV shipped initial commercial quantities and is in talks for larger orders, while a new infusion facility in Pune has been declared and will go for approvals.
- What to watch next quarter: Whether the HAL plant hits its December exhibit-batch deadline, the pace of new product launches against the 15-20 annual target, and any conversion of Prague’s big-order discussions into firm commitments.
HAL Joint Venture: The Near-Term Catalyst
- Plant status: Core manufacturing machine is imported and at the Pimpri, Pune site; most setup-related parts are done; recruitment of manpower has started.
- Timeline: Exhibit batches are expected towards the end or first week of December, with production starting in Q4 FY25 and the first full revenue quarter in Q1 CY25.
- Ramp-up speed: Management expects to hit 95% to 100% capacity utilization within the first couple of months of production.
- Cost discipline: The project has come in under the original estimate after good rounds of negotiations and savings.
- Current-asset disclosure: The increase in current assets on the balance sheet reflects amounts advanced to subsidiary SPL Infusion Private Limited for the HAL business; these will move to investments post issuance of shares once the plant is capitalized.
Srivardhan Khemka: "No, it has actually come under what we had estimated to be. We did have quite a few good round of negotiations and we have managed to save a bunch on it."
Product Portfolio & Competitive Moat
- Scale ambition: The current export product list stands at 145 to 150; management’s eventual goal is to reach 280 to 300 products, the range typical of companies that excel at exports.
- Launch cadence: The company targets 15-20 product launches every year; 6 have been launched so far this year, another 5 are in the works, and a few projects under discussion may commercialize in a month or two.
- Margin trajectory on new products: Initial margins are lower while establishing the supply chain, vendor qualification and first-buyer relationships; once a product is developed and in the kitty, it can be offered to multiple buyers across the world, producing a margin bump as time progresses.
- Competitive advantage: Management cites faster conversion time than anyone in the industry, lower operating cost, a strong R&D team, and a clean record with no blacklisting in any overseas tenders as structural moats. Long-term distributor relationships, some spanning more than 15 years, reinforce the export position.
Ashwani Khemka: "Our conversion time is faster than anyone in the industry. We are not blacklisted in any of the overseas tenders."
Supply Chain & Input Costs
- Freight cost pressure: Geopolitical issues, including Middle East conflicts, are impacting global trade routes via the Suez Canal and through China, delaying shipments and escalating shipping costs to sometimes 2x to 3x of regular freight. Supplies continue despite the challenges.
- Raw material normalization: Raw material prices that increased during the lockdown have been normalizing over the last few quarters and the trend continued this quarter; no major increase is anticipated in a normal operating business environment.
- Capacity utilization: The Bombay plant is running at approximately 70%-75%, unchanged from last quarter; Dehradun is at approximately 45% with slight improvement from own products increasing.
Srivardhan Khemka: "So on both fronts, we are looking at increasing freight costs to the tune of sometimes 2x to 3x of our regular freight. So the challenges remain, but we are still going through with our supplies."
New Ventures: Prague JV & Infusion Expansion
- Prague JV operational: The unit is operational and initial commercial quantities of nutraceutical products are being supplied to the market; the sharp increase in nutraceutical revenues this quarter is attributed to the JV bringing new orders plus a few products for the CIS region that have commercialized.
- Prague stabilization timeline: Operations are still underway and on the way to getting stabilized; it will take a little bit more time, and management says it is too early to comment on capacity utilization because developmental activities make current numbers unrepresentative.
- Prague big-order pipeline: Management is in discussion with a few players regarding large orders and hopes to convert in a quarter or two, but nothing is confirmed yet.
- Prague medium-term potential: If the facility stabilizes and demand continues to grow, management sees a path to EUR0.8 crore to EUR1 crore over the next couple of years, and would probably add another facility bigger than the current one if expansion into that market materializes.
- New infusion facility: A new infusion facility in Pune has been declared and will go for various approvals; the IV business is currently controlled by price regulation (DPCO), with a revision due in December that could increase revenue and bottom line if prices rise.
Srivardhan Khemka: "If we expand into that market, we will probably add on to another facility which might be bigger than what we have right now. So, anything between EUR0.8 crore to EUR1 crore is not something which is difficult to achieve over the course of the next couple of years if everything stabilizes and the demand continues to grow."
Revenue Mix & Geography
- CMO revenue share: Stands at around 9%-10% of revenue, consistent with the past few quarters.
- Domestic market: The increase in domestic revenue this quarter is attributed to certain CDMO client orders executed in the specific quarter; the domestic share of business compared to exports remains lower, consistent with usual guidance.
- Geographical mix outlook: Expected to remain on similar lines, with a possible slight shift between the Middle East and Latin America; a few dossiers have been filed and once approvals are received, commercials might kick in this year.
- FDA site approval: Received FDA site approval from one regulator from a Francophone country, which will enable entry into multiple French-speaking African countries.
- Employee expense increase: As sales increase and new portfolios are added, more technical people with strong backgrounds are being hired; the upcoming Pune infusion project will also add headcount as it goes for approvals.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| HAL exhibit batches | Exhibit batches to begin | End or first week of December 2024 |
| HAL production start | Production to commence | Q4 FY25 |
| HAL first full revenue quarter | Full quarter of revenue contribution | Q1 CY25 |
| HAL capacity ramp | Reach 95%-100% utilization | Within first couple of months of production |
| Product launches | 15-20 products launched per year; 6 done, 5 in the works | FY25 (annual target) |
| Base business capex | INR3.5 crores | FY25 |
| Base business capex | INR5.5 crores | FY26 |
| Export portfolio target | Reach 280-300 products | No date (eventual goal) |
| Prague medium-term revenue | EUR0.8 crore to EUR1 crore achievable | Over the next couple of years, conditional on stabilization and demand growth |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹18.1 cr, +29.5% YoY |
| EBITDA | ₹3.2 cr, +43% YoY |
| EBITDA margin | 17.9%, vs 16.2% in Q2 FY24 |
| Profit after tax | ₹2.3 cr, +34.6% YoY |
| H1 FY25 revenue | ₹34.6 cr, +30% YoY |
| H1 FY25 EBITDA margin | 16.4%, vs 16.3% in H1 FY24 |
| Export/domestic mix | 72%:28% |
| Dosage mix: injectables/tablets/nutraceuticals | 50% / 42.6% / 7.4% |
| Receivables days | 58 days, increase of 26 days vs Mar 24 |
| Inventory days | 28 days |
| Gross block | ₹28.49 cr as of Sep 24 |
| Debt | ₹5 cr on books |
| Cash and cash equivalents | ₹5.2 cr |
| Capex incurred (base business, H1 FY25) | ₹1.46 cr |
| Expected capex (base business, FY25) | ₹3.5 cr |
| Capacity utilization: Bombay plant | ~70%-75% |
| Capacity utilization: Dehradun plant | ~45% |
| CMO revenue share | ~9%-10% |
| Product launches (FY25 to date) | 6 launches, another 5 in the works |
| HAL facility peak revenue expectation | ₹105 cr to ₹110 cr |
| HAL facility EBITDA margin expectation | ~19% |
| Prague business annual top-line estimate | €0.35 cr to €0.4 cr |
| Prague business margin expectation | 25% to 30% |